Imipramine-trazodone

From Psychiatrienet
Revision as of 12:58, 17 November 2009 by Mariska (talk | contribs)
Jump to: navigation, search
Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine
Trazodone
Type Antidepressant
Group other
links
Medscape Trazodone
PubChem 5533
PubMed Trazodone
Kompas (Dutch) Trazodone
Wikipedia Trazodone

Switch medication from imipramine to trazodone.[1] [2]

Nietinrijdenbord.png Stop imipramine
  • Before day 1: gradually reduce dosage of imipramine to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • Day 1: reduce dosage of imipramine to 25 mg/day.
  • Day 8: stop administration of imipramine.
Eenrichtingbord.png Start trazodone

No wash-out period is needed.

  • Day 4: simultaneously start administration of trazodone in a dosage of 150 mg/day.
  • Day 8: continue administration of trazodone. If necessary, increase the dosage of trazodone every 3-4 days with 50 mg to a maximum of 400 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is theoretically possilble, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.